Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit;Farmacocinética de doripenem en pacientes con infecciones tratados en y fuera de una unidad de cuidado intensivo

Annals of Pharmacotherapy

Volumn 47, Issue 5, 2013, Pages 617-627

  Bhalodi, Amira A ^a   Keel, Rebecca A ^a   Quintiliani, Richard ^a   Lodise, Thomas P ^b   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL;

EID: 84877097308     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R789     Document Type: Article

References (25)

1. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67:1027-52.
2. Hagihara M, Kuti JL, Nicolau DP. Predicting doripenem susceptibility based on meropenem and imipenem interpretation of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2012;72:258-62.
3. Package insert. Doribax (doripenem). Raritan, NJ: Ortho-McNeil, Inc., October 2010.
4. Nandy P, Samtani MN, Lin R. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother 2010;54:2354-9.
5. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013;42:1-7.
6. Jaruatanasirikul S, Wongpoowarak W, Kositpantawong N, Aeinlang N, Jullangkoon M. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated gram-negative bacilli pneumonia. Int J Antimicrob Agents 2012;40:434-9.
7. Housman ST, Kuti JL, Nicolau DP. Optimizing antibiotic phar ma co-dynamics in hospital-acquired and ventilator-ac quired bacterial pneumonia. Clin Chest Med 2011;32:439-50.
8. Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012;141:1327-36.
9. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 2011; 27:19-34.
10. Udy AA, Robers JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49:1-16.
11. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012;16:R218.
12. Sutherland C, Nicolau D. Development of an HPLC method for the determination of doripenem in human and mouse serum. J Chromatogr B Analyt Technol Biomed Life Sci 2007;853:123-6.
13. Leary RJ, Schumitzky A, Van Guilder M. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings, fourteenth IEEE symposium on computer-based medical systems. Bethesda, MD: IEEE Computer Society, 2001:389-94.
14. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000;38:415-26.
15. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother 2009;43:220-7.
16. Andes DR, Kiem S, Craig WA. In vivo pharmacodynamic activity of a new carbapenem, doripenem, against multiple bacteria in a murine thigh infection model (abstract A-308). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL.
17. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005;49:3944-7.
18. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of r-lactams. Crit Care 2011;15: R206.
19. Ikawa K, Morikawa N, Uehara S, et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents 2009;33:276-9.
20. Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T. Pharmacodynamic assessment of doripenem in peritoneal fluid against gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation. Diagn Microbiol Infect Dis 2008;62:292-7.
21. Udy AA, Varghese JM, Altukroni M, et al. Sub-therapeutic initial-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012;142:30-9.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
23. Eagye KJ, Banevicius MA, Nicolau DP. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy. Crit Care Med 2012;40:1329-32.
24. Samtani MN, Flamm R, Kaniga K, Nandy P. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010;54:2360-4.
25. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-96.